{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:24:27Z","timestamp":1794007467488,"version":"4.8.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The role of cytokines in the systemic inflammatory response (SIR) is now well established. This is in keeping with the role of the SIR in tumorigenesis, malignant spread, and the development of cachexia. However, the relationship between performance status\/systemic inflammation frameworks and cytokine profiles is not clear. The aim of the present study was to examine the relationship between the Eastern cooperative oncology group performance status\/modified Glasgow prognostic score (ECOG-PS\/mGPS) and cooperative oncology group performance status\/neutrophil platelet score (ECOG-PS\/NPS) frameworks and their cytokine profile in patients with advanced cancer.<\/jats:p>\n                    <jats:p>\n                      This was a retrospective interrogation of data already collected as part of a recent clinical trial (NCT00676936). The relationship between the independent variables (ECOG-PS\/mGPS and ECOG-PS\/NPS frameworks), and dependent variables (cytokine levels) was examined using independent Mann\u2013Whitney\n                      <jats:italic toggle=\"yes\">U<\/jats:italic>\n                      and Kruskal Wallis tests where appropriate.\n                    <\/jats:p>\n                    <jats:p>\n                      Of the 40 patients included in final analysis the majority had evidence of an SIR assessed by mGPS (78%) or NPS (53%). All patients died on follow-up and the median survival was 91 days (4\u2013933 days). With increasing ECOG-PS there was a higher median value of Interleukin 6 (IL-6,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.016) and C-reactive protein (CRP,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.01) and lower albumin (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.01) and poorer survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001). With increasing mGPS there was a higher median value of IL-6 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.016), Macrophage migration inhibitory factor (MIF,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.010), erythrocyte sedimentation rate (ESR,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.01) and poorer survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.01). With increasing NPS there was a higher median value of TGF-\u03b2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001) and C-reactive protein (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.020) and poor survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.001). When those patients with an ECOG-PS 0\/1 and mGPS0 were compared with those patients with an ECOG-PS 2 and mGPS2 there was a higher median value of IL-6 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.017) and poorer survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001). When those patients with an ECOG-PS 0\/1 and NPS0 were compared with those patients with an ECOG-PS 2 and NPS1\/2 there was a higher median value of IL-6 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.002), TGF-\u03b2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001) and poorer survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.01).\n                    <\/jats:p>\n                    <jats:p>In patients with advanced cancer IL-6 was associated with the ECOG-PS\/mGPS and ECOG-PS\/NPS frameworks and survival in patients with advanced cancer. Therefore, the present work provides supporting evidence that agents targeting IL-6 are worthy of further exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000017019","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T22:00:56Z","timestamp":1568325656000},"page":"e17019","source":"Crossref","is-referenced-by-count":15,"title":["An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer"],"prefix":"10.1097","volume":"98","author":[{"given":"Ross D.","family":"Dolan","sequence":"first","affiliation":[{"name":"Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.A.","family":"Laird","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Klepstad","sequence":"additional","affiliation":[{"name":"Department Intensive Care Medicine, St Olavs University Hospital, 7006 Trondheim and European Palliative Care Research Centre (PRC), Oslo University Hospital and Institute of Clinical Medicine, Oslo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Kaasa","sequence":"additional","affiliation":[{"name":"European Palliative Care Research Centre (PRC), Oslo University Hospital and Institute of Clinical Medicine, Oslo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Horgan","sequence":"additional","affiliation":[{"name":"Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8rnulf","family":"Paulsen","sequence":"additional","affiliation":[{"name":"European Palliative Care Research Centre (PRC), Oslo University Hospital and Institute of Clinical Medicine and Palliative Care Unit, Telemark Hospital Trust, Skien, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,9]]},"reference":[{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.2015.65.7742","article-title":"Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response","volume":"34","author":"Laird","year":"2016","journal-title":"J Clin Oncol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"16717","DOI":"10.1038\/s41598-017-16955-5","article-title":"The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis","volume":"7","author":"Dolan","year":"2017","journal-title":"Sci Rep"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.critrevonc.2017.06.002","article-title":"The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis","volume":"116","author":"Dolan","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ejso.2018.02.209","article-title":"Inflammation and cancer: what a surgical oncologist should know","volume":"44","author":"Dupre","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"e0142159","DOI":"10.1371\/journal.pone.0142159","article-title":"The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers","volume":"10","author":"Watt","year":"2015","journal-title":"PloS One"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1158\/1078-0432.CCR-13-1066","article-title":"Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system","volume":"19","author":"Laird","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R8-20230914","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0474","article-title":"How long have I got?\u201d\u2013 A prospective cohort study comparing validated prognostic factors for use in patients with advanced cancer","author":"Simmons","year":"2019","journal-title":"The Oncol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ncb3015","article-title":"The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis","volume":"16","author":"McAllister","year":"2014","journal-title":"Nat Cell Biol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(08)60241-X","article-title":"Tumour immunity: effector response to tumour and role of the microenvironment","volume":"371","author":"Mantovani","year":"2008","journal-title":"Lancet"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"e0177620","DOI":"10.1371\/journal.pone.0177620","article-title":"The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer","volume":"12","author":"Paulsen","year":"2017","journal-title":"PloS One"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/SLA.0000000000001122","article-title":"Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host","volume":"263","author":"Park","year":"2016","journal-title":"Ann Surg"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41416-018-0095-9","article-title":"The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores","volume":"119","author":"Dolan","year":"2018","journal-title":"Br J Cancer"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1200\/JCO.2013.54.3926","article-title":"Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial, Journal of clinical oncology: official","volume":"32","author":"Paulsen","year":"2014","journal-title":"J Am Soc Clin Oncol"},{"key":"R17-20230914","first-page":"4561","article-title":"Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients","volume":"31","author":"Makimura","year":"2011","journal-title":"Anticancer Res"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrc2507","article-title":"Cytokines and their relationship to the symptoms and outcome of cancer","volume":"8","author":"Seruga","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.bbi.2010.03.009","article-title":"Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy","volume":"24","author":"Wang","year":"2010","journal-title":"Brain Behav Immun"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"434010","DOI":"10.1155\/2013\/434010","article-title":"Cytokine levels in the serum of healthy subjects","volume":"2013","author":"Kleiner","year":"2013","journal-title":"Mediators Inflamm"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"e1093722","DOI":"10.1080\/2162402X.2015.1093722","article-title":"Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis","volume":"5","author":"Lippitz","year":"2016","journal-title":"Oncoimmunology"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/bjc.2012.456","article-title":"Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma","volume":"107","author":"Kantola","year":"2012","journal-title":"Br J Cancer"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/bjc.2013.161","article-title":"Comment on 'stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma\u2019","volume":"108","author":"Guthrie","year":"2013","journal-title":"Br J Cancer"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.bbi.2012.05.004","article-title":"A systematic review of the association between immunogenomic markers and cancer-related fatigue","volume":"26","author":"Saligan","year":"2012","journal-title":"Brain Behav Immun"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.pain.2010.10.035","article-title":"Cancer pain and its relationship to systemic inflammation: an exploratory study","volume":"152","author":"Laird","year":"2011","journal-title":"Pain"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/bjc.1996.294","article-title":"The relationship between weight loss and interleukin 6 in non-small-cell lung cancer","volume":"73","author":"Scott","year":"1996","journal-title":"Br J Cancer"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00000658-199101000-00005","article-title":"Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer","volume":"213","author":"Fearon","year":"1991","journal-title":"Ann Surg"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ctrv.2012.07.003","article-title":"Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer?","volume":"39","author":"Guthrie","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/SPC.0000000000000398","article-title":"Targeting IL-1alpha in cancer cachexia: a narrative review","volume":"12","author":"McDonald","year":"2018","journal-title":"Curr Opin Support Palliat Care"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol Rev"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578","article-title":"Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed","volume":"33","author":"Hurwitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.critrevonc.2018.09.016","article-title":"The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review","volume":"132","author":"Dolan","year":"2018","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:20:31Z","timestamp":1694712031000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":36,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017019","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}